← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Bruton's tyrosine kinase (BTK) inhibitors
ibrutinib
L01EL01
Forms & Strengths
- Capsules: 70 mg, 140 mg
- Tablets: 70 mg, 140 mg
Adult Dosing
- 420 mg orally once daily for CLL/SLL
- 560 mg orally once daily for MCL
- 420 mg orally once daily for WM
- 560 mg orally once daily for MZL
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- No recommended dose for patients under 18 years
Indications
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
- Mantle cell lymphoma (MCL)
- Waldenstrom macroglobulinemia (WM)
- Marginal zone lymphoma (MZL)
Mechanism of Action
- Covalent inhibitor of Bruton's tyrosine kinase (BTK)
- Disrupts B-cell receptor signaling
- Inhibits cell proliferation and survival
Contraindications
- Hypersensitivity to ibrutinib
- None known, but caution with severe hepatic impairment
Adverse Reactions
- Diarrhea
- Fatigue
- Nausea
- Bleeding events
- Pneumonia
- Neutropenia
- Thrombocytopenia
Drug Interactions
- Strong CYP3A4 inhibitors increase ibrutinib exposure
- Strong CYP3A4 inducers decrease ibrutinib exposure
- Avoid concomitant use with warfarin and other anticoagulants
Curated Content: Needs Vetting Before Put to Clinical Use